思道医药科技

Sidao MedTech is a clinical-stage biopharmaceutical company headquartered in Shanghai, China, specializing in the development of innovative cancer immunotherapies. The company was established by industry veterans with significant experience in global drug discovery and development, aiming to address high unmet medical needs in oncology. Sidao's primary focus is its lead candidate, SD-101, a potent Toll-like receptor 9 (TLR9) agonist designed to stimulate both innate and adaptive immune systems within the tumor microenvironment. Through a strategic licensing agreement with Dynavax Technologies, Sidao MedTech is advancing SD-101 in the Greater China region, primarily investigating its efficacy in combination with PD-1/PD-L1 inhibitors. The company's pipeline is centered on assets that can potentially transform the treatment landscape for solid tumors such as head and neck cancer and melanoma.